Form 4: Guardant Health Co-CEO Sells $9.4M in Stock

Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported the sale of 90,565 shares of common stock for approximately $9.4 million.

Summary

• Helmy Eltoukhy, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), sold a total of 90,565 shares of the company's common stock.
• The transactions occurred on December 15, 2025, and were executed under a Rule 10b5-1 trading plan.
• The first sale involved 83,945 shares at a weighted average price of $103.8012 per share, with prices ranging from $103.02 to $104.01.
• The second sale involved 6,620 shares at a weighted average price of $104.0224 per share, with prices ranging from $104.020 to $104.055.
• The total value of the shares sold is approximately $9,403,690.
• Following these transactions, Mr. Eltoukhy directly beneficially owns 2,047,143 shares of Guardant Health common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale, often pre-scheduled under a 10b5-1 plan, which typically has a neutral impact on company sentiment unless the scale or timing is unusual. This transaction appears to be a standard disclosure.

Negatives

• A Co-Chief Executive Officer and Director sold a significant number of shares (90,565 shares) of company stock.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape for Guardant Health, which operates in the precision oncology and liquid biopsy space.

Stakeholder Impact

• Shareholders may note the sale of shares by a key executive, which could be interpreted in various ways, though often these sales are part of pre-arranged financial planning (10b5-1 plan).

Key Dates

Recommendation

The reported insider sale by a Co-CEO, while significant in value, is often a pre-planned event under a Rule 10b5-1 trading plan for diversification or liquidity purposes. Without additional context on company performance, strategic shifts, or broader market conditions, this single transaction does not warrant a change from a 'hold' recommendation. Investors should monitor future filings and company announcements for more comprehensive insights.

Keywords

Guardant Health, GH, Helmy Eltoukhy, Insider Trading, Stock Sale, Form 4, CEO, Director, 10b5-1 Plan